1
|
Feng Z, Zhu S, Li W, Yao M, Song H, Wang RB. Current approaches and strategies to identify Hedgehog signaling pathway inhibitors for cancer therapy. Eur J Med Chem 2022; 244:114867. [DOI: 10.1016/j.ejmech.2022.114867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2022] [Revised: 10/19/2022] [Accepted: 10/19/2022] [Indexed: 11/30/2022]
|
2
|
Lu J, Guan H, Wu D, Hu Z, Zhang H, Jiang H, Yu J, Zeng K, Li H, Zhang H, Pan C, Cai D, Yu X. Pseudolaric acid B ameliorates synovial inflammation and vessel formation by stabilizing PPARγ to inhibit NF-κB signalling pathway. J Cell Mol Med 2021; 25:6664-6678. [PMID: 34117708 PMCID: PMC8278075 DOI: 10.1111/jcmm.16670] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Revised: 04/10/2021] [Accepted: 05/08/2021] [Indexed: 12/16/2022] Open
Abstract
Synovial macrophage polarization and inflammation are essential for osteoarthritis (OA) development, yet the molecular mechanisms and regulation responsible for the pathogenesis are still poorly understood. Here, we report that pseudolaric acid B (PAB) attenuated articular cartilage degeneration and synovitis during OA. PAB, a diterpene acid, specifically inhibited NF-κB signalling and reduced the production of pro-inflammatory cytokines, which further decreased M1 polarization and vessel formation. We further provide in vivo and in vitro evidences that PAB suppressed NF-κB signalling by stabilizing PPARγ. Using PPARγ antagonist could abolish anti-inflammatory effect of PAB and rescue the activation of NF-κB signalling during OA. Our findings identify a previously unrecognized role of PAB in the regulation of OA and provide mechanisms by which PAB regulates NF-κB signalling through PPARγ, which further suggest targeting synovial inflammation or inhibiting vessel formation at early stage could be an effective preventive strategy for OA.
Collapse
Affiliation(s)
- Jiansen Lu
- Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.,Department of Orthopedics, Orthopedic Hospital of Guangdong Province, Academy of Orthopedics·Guangdong Province, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.,Department of Joint Surgery, the Fifth Affiliated Hospital of Southern Medical University Guangdong Province, Guangzhou, China
| | - Hong Guan
- Department of Orthopedics, Orthopedic Hospital of Guangdong Province, Academy of Orthopedics·Guangdong Province, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.,The Third School of Clinical Medicine, Southern Medical University, Guangzhou, China.,Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, Guangzhou, China.,Department of Joint Surgery, Center for Orthopaedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China
| | - Dan Wu
- Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
| | - Zhiqiang Hu
- Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
| | - Hongbo Zhang
- Department of Orthopedics, Orthopedic Hospital of Guangdong Province, Academy of Orthopedics·Guangdong Province, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.,The Third School of Clinical Medicine, Southern Medical University, Guangzhou, China.,Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, Guangzhou, China.,Department of Joint Surgery, Center for Orthopaedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China
| | - Huaji Jiang
- Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
| | - Jingyao Yu
- School of Basic Medical Sciences, Gannan Medical University, Ganzhou, China
| | - Ke Zeng
- Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
| | - Hongyu Li
- Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
| | - Haiyan Zhang
- Department of Orthopedics, Orthopedic Hospital of Guangdong Province, Academy of Orthopedics·Guangdong Province, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.,The Third School of Clinical Medicine, Southern Medical University, Guangzhou, China.,Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, Guangzhou, China.,Department of Joint Surgery, Center for Orthopaedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China
| | - Chenglong Pan
- Department of Joint Surgery, the Fifth Affiliated Hospital of Southern Medical University Guangdong Province, Guangzhou, China
| | - Daozhang Cai
- Department of Orthopedics, Orthopedic Hospital of Guangdong Province, Academy of Orthopedics·Guangdong Province, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.,The Third School of Clinical Medicine, Southern Medical University, Guangzhou, China.,Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, Guangzhou, China.,Department of Joint Surgery, Center for Orthopaedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China
| | - Xiao Yu
- Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.,Department of Joint Surgery, the Fifth Affiliated Hospital of Southern Medical University Guangdong Province, Guangzhou, China.,Guangdong Provincial Key Lab of Single Cell Technology and Application, Southern Medical University, Guangzhou, China
| |
Collapse
|
3
|
Su J, Wang K, Zhou X, Wang Y, Xu J, Tao L, Zeng X, Chen N, Bai X, Li X. B-cell-specific-peroxisome proliferator-activated receptor γ deficiency augments contact hypersensitivity with impaired regulatory B cells. Immunology 2018; 156:282-296. [PMID: 30471095 DOI: 10.1111/imm.13027] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Revised: 11/08/2018] [Accepted: 11/13/2018] [Indexed: 12/13/2022] Open
Abstract
Nuclear receptor peroxisome proliferator-activated receptor γ (PPAR-γ) activation can prevent immunoinflammatory disorders and diabetes. B cells play protective roles during inflammation as well. However, the roles of endogenous PPAR-γ in the regulatory properties of B cells to relieve inflammation remain unknown. Here, we developed B-cell-specific PPAR-γ knockout (B-PPAR-γ-/- ) mice and found that the conditional deletion of PPAR-γ in B cells resulted in exaggerated contact hypersensitivity (CHS). Meanwhile, interferon-γ (IFN-γ) of CD4+ CD8+ T cells was up-regulated in B-PPAR-γ-/- mice in CHS. This showed that the regulatory function of B cells in B-PPAR-γ-/- mice declined in vivo. Whereas splenic CD5+ CD1dhi regulatory B-cell numbers and peripheral regulatory T-cell numbers were not changed in naive B-PPAR-γ-/- mice. Loss of PPAR-γ in B cells also did not affect either CD86 or FasL expression in splenic CD5+ CD1dhi regulatory B cells after activation. Notably, interleukin-10 (IL-10) production in CD5+ CD1dhi regulatory B cells reduced in B-PPAR-γ-deficient mice. In addition, functional IL-10-producing CD5+ CD1dhi regulatory B cells decreased in B-PPAR-γ-/- mice in the CHS model. These findings were in accordance with augmented CHS. The current work indicated the involvement of endogenous PPAR-γ in the regulatory function of B cells by disturbing the expansion of IL-10-positive regulatory B cells.
Collapse
Affiliation(s)
- Jianbing Su
- Laboratory of Anti-inflammatory and Immunomodulatory Pharmacology, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.,Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
| | - Keng Wang
- Laboratory of Anti-inflammatory and Immunomodulatory Pharmacology, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.,Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
| | - Xuan Zhou
- Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.,State Key Laboratory of Organ Failure Research, Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
| | - Yiyuan Wang
- Laboratory of Anti-inflammatory and Immunomodulatory Pharmacology, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.,Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
| | - Jialan Xu
- Laboratory of Anti-inflammatory and Immunomodulatory Pharmacology, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.,Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
| | - Lei Tao
- Laboratory of Anti-inflammatory and Immunomodulatory Pharmacology, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.,Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
| | - Xiangzhou Zeng
- Laboratory of Anti-inflammatory and Immunomodulatory Pharmacology, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.,Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
| | - Nana Chen
- Laboratory of Anti-inflammatory and Immunomodulatory Pharmacology, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.,Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
| | - Xiaochun Bai
- State Key Laboratory of Organ Failure Research, Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
| | - Xiaojuan Li
- Laboratory of Anti-inflammatory and Immunomodulatory Pharmacology, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.,Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
| |
Collapse
|
4
|
Fan M, Li Y, Yao C, Liu X, Liu X, Liu J. Dihydroartemisinin derivative DC32 attenuates collagen-induced arthritis in mice by restoring the Treg/Th17 balance and inhibiting synovitis through down-regulation of IL-6. Int Immunopharmacol 2018; 65:233-243. [PMID: 30336338 DOI: 10.1016/j.intimp.2018.10.015] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2018] [Revised: 10/09/2018] [Accepted: 10/10/2018] [Indexed: 12/12/2022]
Abstract
Imbalance of Treg/Th17 and chronic synovitis characterized by the recruitment and infiltration of inflammatory cells are the typical features of rheumatoid arthritis (RA). IL-6 promotes the differentiation and function of Th17 cells, which contributes to the imbalance of Treg/Th17 and aggravates lymphocytic infiltration in joints. DC32, a dihydroartemisinin derivative, was found to have anti-inflammatory and immunosuppressive activities in previous study. The aim of this study is to evaluate the effects and mechanisms of DC32 in immunodeficiency and inflammatory infiltration of RA. In vivo, the antirheumatic effect of DC32 was evaluated in a collagen-induced arthritis (CIA) mouse model in DBA/1 mice. The percentages of Treg and Th17 and transcription of IL-6 in the spleen were assayed. In vitro, a coculture system of ConA-activated lymphocytes and fibroblast-like synoviocytes (FLSs) from rat with adjuvant arthritis (AA) was established. The effects and mechanisms of DC32 on synovitis were investigated. It was shown that DC32 inhibited footpad swelling and lymphocytic infiltration in mice with CIA and significantly restored the Treg/Th17 balance by reducing the transcription of IL-6 in splenocytes. DC32 significantly inhibited the lymphocyte-induced invasion and migration of FLSs by decreasing the secretion of MMPs (MMP-2, MMP-3) in vitro. DC32 also reduced the transcription of chemokines (CXCL12, CX3CL1) and IL-6 in FLSs, as well as IL-6 levels in the supernatant. These results demonstrated that DC32 may attenuate RA by restoring Treg/Th17 balance and inhibiting lymphocytic infiltration through downregulation of the expression and transcription of IL-6. This study supports the potential of DC32 to down-regulate IL-6 for the treatment of RA and other related autoimmune diseases.
Collapse
Affiliation(s)
- Menglin Fan
- State Key Laboratory of Natural Products, Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China
| | - Yanan Li
- State Key Laboratory of Natural Products, Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China
| | - Chunhua Yao
- State Key Laboratory of Natural Products, Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China
| | - Xiufeng Liu
- State Key Laboratory of Natural Products, Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China
| | - Xuming Liu
- School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu 211198, China.
| | - Jihua Liu
- State Key Laboratory of Natural Products, Jiangsu Key Laboratory of TCM Evaluation and Translational Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China.
| |
Collapse
|
5
|
Yang Z, Liu M, Wang W, Wang Y, Cao B, Gao Y, Chen H, Li T. Pseudolaric acid B attenuates atopic dermatitis-like skin lesions by inhibiting interleukin-17-induced inflammation. Sci Rep 2017; 7:7918. [PMID: 28801611 PMCID: PMC5554149 DOI: 10.1038/s41598-017-08485-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2017] [Accepted: 07/11/2017] [Indexed: 12/19/2022] Open
Abstract
Pseudolaric acid B (PB), isolated from the extract of the root bark of Pseudolarix kaempferi Gordon, has been used as a traditional remedy for the treatment of skin diseases. However, the information of PB on atopic dermatitis (AD) remains largely unknown. In the present study, oral administration with PB improved the severity scores of AD-like skin lesions dose-dependently in NC/Nga mice through reducing serum IgE, pro-inflammatory cytokines, and the infiltration of inflammatory cells. In addition, PB significantly attenuated the levels of IL-17 and IL-22, and the proportion of Th17 cells in NC/Nga mice, as well as decreased IL-17-induced inflammation in RAW264.7 cells. Moreover, PB inhibited the phosphorylation of IκBα and miR-155 expression both in NC/Nga mice and in IL-17-stimulated RAW264.7 cells, which could be reversed by GW9662, a specific antagonist for PPARγ. The incorporation of GW9662 reversed the inhibitory effect of PB on the RORγ-mediated activation of the Il17 promoter. Transfection with PPARγ luciferase reporter gene further demonstrated the enhancement of PB on PPARγ transactivation. These findings indicate that PB could ameliorate AD-like skin lesions by inhibiting IL-17-induced inflammation in a PPARγ-dependent manner, which would provide experimental evidence of PB for the therapeutic potential on AD and other inflammatory skin diseases.
Collapse
Affiliation(s)
- Zhen Yang
- Department of Science Research, Logistics University of Chinese People's Armed Police Force, Tianjin, 300309, P.R. China
| | - Meilun Liu
- Department of Pharmacognosy and Pharmaceutics, Logistics University of Chinese People's Armed Police Force, Tianjin, 300309, P.R. China
| | - Wei Wang
- Department of Urology, The Affiliated Hospital of Logistics University of Chinese People's Armed Police Force, Tianjin, 300162, P.R. China
| | - Yiteng Wang
- Department of Pharmacognosy and Pharmaceutics, Logistics University of Chinese People's Armed Police Force, Tianjin, 300309, P.R. China
| | - Bo Cao
- Department of Pharmacognosy and Pharmaceutics, Logistics University of Chinese People's Armed Police Force, Tianjin, 300309, P.R. China
| | - Ying Gao
- Department of Pharmacognosy and Pharmaceutics, Logistics University of Chinese People's Armed Police Force, Tianjin, 300309, P.R. China
| | - Hong Chen
- Department of Pharmacognosy and Pharmaceutics, Logistics University of Chinese People's Armed Police Force, Tianjin, 300309, P.R. China.
| | - Tan Li
- Department of Pathogen Biology and Immunology, Logistics University of Chinese People's Armed Police Force, Tianjin, 300309, P.R. China.
| |
Collapse
|
6
|
Liu ML, Sun D, Li T, Chen H. A Systematic Review of the Immune-Regulating and Anticancer Activities of Pseudolaric Acid B. Front Pharmacol 2017; 8:394. [PMID: 28701952 PMCID: PMC5487521 DOI: 10.3389/fphar.2017.00394] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2017] [Accepted: 06/06/2017] [Indexed: 01/01/2023] Open
Abstract
Cortex pseudolaricis, the root bark of Pseudolarix kaempferi Gord, has been used to treat tinea and other skin diseases for the antimicrobial activities in Traditional Chinese Medicine (TCM). Pseudolaric acid B (PAB) has been identified as the major component responsible for the action of C. pseudolaricis. Recently, PAB has been demonstrated to be used as novel treatments for cancer, immune disorders, inflammatory diseases, and immunosuppression. However, the mechanisms through which PAB exerts its properties are not understood well, and little attention in the literature has been given to review its pharmacological activities before. In this review, we performed a systematic summary of the literature with respect to the anticancer, immunosuppressive and anti-inflammatory properties of PAB and its derivatives. Currently available data suggest that PAB is a promising immunosuppressive and anti-inflammatory agent candidate and should be explored further in cancer treatment and prevention.
Collapse
Affiliation(s)
- Mei-Lun Liu
- Department of Pharmacognosy and Pharmaceutics, Logistics University of the Chinese People's Armed Police ForceTianjin, China
| | - Dan Sun
- Department of Pharmacognosy and Pharmaceutics, Logistics University of the Chinese People's Armed Police ForceTianjin, China
| | - Tan Li
- Department of Pathogen Biology and Immunology, Logistics University of the Chinese People's Armed Police ForceTianjin, China
| | - Hong Chen
- Department of Pharmacognosy and Pharmaceutics, Logistics University of the Chinese People's Armed Police ForceTianjin, China
| |
Collapse
|
7
|
Hu YE, Dai SF, Liu Y, Wang B, Qu W. Study on the therapeutic mechanisms of pseudolaric acid in mice with allergic contact dermatitis. ASIAN PAC J TROP MED 2016; 9:668-71. [PMID: 27393095 DOI: 10.1016/j.apjtm.2016.05.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2016] [Revised: 05/16/2016] [Accepted: 05/23/2016] [Indexed: 11/28/2022] Open
Abstract
OBJECTIVE To study the therapeutic mechanisms of pseudolaric acid on allergic contact dermatitis in mice. METHODS A total of 50 BALB/C mice were selected and randomly divided into control group, model group, and treatment A, B, C groups with 10 rats in each group. ACD model was established in model group, and treatment A, B, C groups but not in control group. Model group received no treatment, but treatment A, B, C groups were treated with external application of the concentration of 0.1%, 0.2% and 0.4% of the pseudolaric acid for the lesions of ear skin. And the weight gain and the swelling degree of the mice' ear were recorded, weight of thymus and spleen were measured. Spleen suspension was prepared to test T lymphocyte and B lymphocyte levels of mice in five groups. Changes in serum IFN-γ, IL-4 and IL-10 levels were tested through the enzyme linked immunosorbent assay (ELISA). RESULTS The weight gain of mice in model group were significant lower than those of mice in the control group and the treatment A, B, C groups (P < 0.05). Weight gain of mice in treatment A, B groups were significant lower than that of control group (P < 0.05), but the difference in weight gain between treatment C group and control group showed no significant difference (P > 0.05). The swelling degree and the weight of mice ears in model group were significant higher than those of mice in control group and treatment A, B, C groups (P < 0.05). Swelling degree and the weight of mice ears of treatment A, B, C groups were obviously higher than that of control group (P < 0.05). The swelling degree and weight of mice' ears in treatment A, B, C groups were decreased with the increase of the drug dosage, but comparison between A, B and C group showed statistically differences (P < 0.05). The thymus and spleen index of mice in model group were significant higher than those of the other four groups (P < 0.05), among the four groups, thymus and spleen index of treatment A and B group were higher than control group and treatment C group (P < 0.05). The stimulation index of T and B cells of mice in model group was significantly higher than the rest four groups (P < 0.05). The serum IFN-γ level of mice in control group and treatment A, B and C group was obviously lower than that of mice in model group (P < 0.05). The serum IFN-γ level of mice in treatment A, B and C group were decreased with the increasing of the drug dosage, and the level of C group was obviously lower than that of A and B group (P < 0.05). CONCLUSION The pseudolaric acid has anti-inflammation and immune adjustment the effects showing a remarkable therapeutic effects for the ACD mice.
Collapse
Affiliation(s)
- Yin-E Hu
- Dermatology Department, Henan University Affiliated Huaihe Hospital, Kaifeng, Henan, 475000, China
| | - Shu-Fang Dai
- Dermatology Department, Henan University Affiliated Huaihe Hospital, Kaifeng, Henan, 475000, China.
| | - Yang Liu
- Dermatology Department, Henan University Affiliated Huaihe Hospital, Kaifeng, Henan, 475000, China
| | - Bin Wang
- Dermatology Department, Henan University Affiliated Huaihe Hospital, Kaifeng, Henan, 475000, China
| | - Wei Qu
- Dermatology Department, Henan University Affiliated Huaihe Hospital, Kaifeng, Henan, 475000, China
| |
Collapse
|
8
|
Wan T, Xu T, Pan J, Qin M, Pan W, Zhang G, Wu Z, Wu C, Xu Y. Microemulsion based gel for topical dermal delivery of pseudolaric acid B: In vitro and in vivo evaluation. Int J Pharm 2015. [DOI: 10.1016/j.ijpharm.2015.07.058] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
9
|
Li T, Chen H, Yang Z, Wang W, Wang YT, Zhang LM, Zhao JH, Zhou X, Li YM. A novel Pseudolaric acid B derivative, Hexahydropseudolaric acid B, exterts an immunomodulatory effect in vitro/in vivo evaluation. Eur J Pharmacol 2014; 745:10-8. [PMID: 25446920 DOI: 10.1016/j.ejphar.2014.10.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2014] [Revised: 10/01/2014] [Accepted: 10/06/2014] [Indexed: 02/02/2023]
Abstract
Identification of immunosuppressants from natural sources has a proven track record in immune mediated disorders. Pseudolaric acid B is a diterpenoid isolated from the roots of Pseudolarix amabilis, possessing potent immunomodulatory effect. However, the cytotoxicity limits its future clinical application. The purpose of this study was to investigate the immunosuppressive activity of Hexahydropseudolaric acid B, a Pseudolaric acid B derivative, on T cell-mediated immune response both in vitro and in vivo, and investigated its immunomodulatory effect to develop a more ascendant immunosuppressive agent. The results showed that Hexahydropseudolaric acid B could exert more preferable immunosuppressive activity and lower cytotoxicity than Pseudolaric acid B. Hexahydropseudolaric acid B significantly inhibited T cell proliferation activated by mitogen and alloantigen without obvious cytotoxicity in vitro. Furthermore, Hexahydropseudolaric acid B could ameliorate ear swelling in a mouse model of 2,4-dinitrofluorobenzene-induced delayed-type hypersensitivity in vivo. Mechanistic study revealed that Hexahydropseudolaric acid B could enhance regulatory T cells via promoting Foxp3 expression and TGF-β level, accompanied by attenuating Akt activation, blocking p38MAPK/MK2-HSP27 signal cascades, and up-regulating PPAR-γ expression. Taken together, these results suggest that Hexahydropseudolaric acid B exerts more preferable immunosuppressive activity than its precursor Pseudolaric acid B by affecting multiple targets, which support the need for continued efforts to characterize the efficacy of HPAB as a promising and safe candidate to treat immune-related diseases.
Collapse
Affiliation(s)
- Tan Li
- Department of Pathogen Biology and Immunology, Logistics University of the Chinese People׳s Armed Police Force, Tianjin 300309, China; Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, Institute of Cardiovascular Disease and Heart Center, The Affiliated Hospital of Logistics University of the Chinese People׳s Armed Police Force, Tianjin 300162, China.
| | - Hong Chen
- Department of Pharmacognosy and Pharmaceutics, Logistics University of the Chinese People׳s Armed Police Force, Tianjin 300309, China; Tianjin Key Laboratory for Prevention and Control of Occupational and Environmental Hazard, Logistics University of the Chinese People׳s Armed Police Force, Tianjin 300309, China.
| | - Zhen Yang
- Pingjin Hospital, Logistics University of the Chinese People׳s Armed Police Force, Tianjin 300162, China
| | - Wei Wang
- Pingjin Hospital, Logistics University of the Chinese People׳s Armed Police Force, Tianjin 300162, China
| | - Yi-teng Wang
- Department of Pharmacognosy and Pharmaceutics, Logistics University of the Chinese People׳s Armed Police Force, Tianjin 300309, China
| | - Li-ming Zhang
- Department of Pharmacognosy and Pharmaceutics, Logistics University of the Chinese People׳s Armed Police Force, Tianjin 300309, China
| | - Ji-hong Zhao
- Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, Institute of Cardiovascular Disease and Heart Center, The Affiliated Hospital of Logistics University of the Chinese People׳s Armed Police Force, Tianjin 300162, China; Pingjin Hospital, Logistics University of the Chinese People׳s Armed Police Force, Tianjin 300162, China
| | - Xin Zhou
- Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, Institute of Cardiovascular Disease and Heart Center, The Affiliated Hospital of Logistics University of the Chinese People׳s Armed Police Force, Tianjin 300162, China; Pingjin Hospital, Logistics University of the Chinese People׳s Armed Police Force, Tianjin 300162, China
| | - Yu-ming Li
- Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, Institute of Cardiovascular Disease and Heart Center, The Affiliated Hospital of Logistics University of the Chinese People׳s Armed Police Force, Tianjin 300162, China; Pingjin Hospital, Logistics University of the Chinese People׳s Armed Police Force, Tianjin 300162, China
| |
Collapse
|
10
|
Li T, Wang W, Zhao JH, Zhou X, Li YM, Chen H. Pseudolaric acid B inhibits T-cell mediated immune response in vivo via p38MAPK signal cascades and PPARγ activation. Life Sci 2014; 121:88-96. [PMID: 25497712 DOI: 10.1016/j.lfs.2014.11.020] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2014] [Revised: 11/03/2014] [Accepted: 11/26/2014] [Indexed: 11/25/2022]
Abstract
AIMS Pseudolaric acid B (PAB) has been prescribed for its potent immunomodulatory effect. However, the detail of mechanism remains to be demonstrated. The purpose of this study is to further clarify the mechanism of PAB on T-cell mediated immune response in vivo. MAIN METHODS Investigations were carried to ascertain the pharmacological effect of PAB in a delayed-type hypersensitivity (DTH) mouse model of T-cell mediated immune response. Histological assessment was examined by hematoxylin and eosin staining. Affymetrix GeneChip® Mouse Genome 430 2.0 arrays were employed to evaluate the expression profile of PAB. Western blot was performed to detect p38MAPK signal cascades, including p38MAPK, ATF-2, MK2, and HSP27. Finally, TNF-α level was analyzed by ELISA, and Jurkat T cells were treated with PAB to determine its role on PPARγ activation using a reporter gene assay. KEY FINDINGS The results showed that PAB (5, 10, and 20mg/kg) could lead to a marked improvement for ear swelling and inflammatory infiltrate in DTH mice dose-dependently. According to the associated biological pathways from microarray analysis, PAB resulted in the restoration of abnormal immune-related gene expression linked to MAPK and PPAR signaling pathways. Moreover, PAB inhibited the activation of p38MAPK, ATF-2, MK2, and HSP27 significantly, as well as the production of TNF-α, which was reversed by GW9662, a specific antagonist for PPARγ. In addition, treatment with PAB also increased the transcriptional activity of PPARγ in a dose-dependent manner. SIGNIFICANCE These results provide us with novel insights into pharmacological action of PAB as a potential immunomodulator for the treatment of immune-related diseases.
Collapse
Affiliation(s)
- Tan Li
- Department of Pathogen Biology and Immunology, Logistics University of the Chinese People's Armed Police Force, Tianjin, PR China; Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, Logistics University of the Chinese People's Armed Police Force, Tianjin, PR China.
| | - Wei Wang
- Pingjin Hospital, Logistics University of the Chinese People's Armed Police Forces, Tianjin, PR China
| | - Ji-hong Zhao
- Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, Logistics University of the Chinese People's Armed Police Force, Tianjin, PR China; Pingjin Hospital, Logistics University of the Chinese People's Armed Police Forces, Tianjin, PR China
| | - Xin Zhou
- Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, Logistics University of the Chinese People's Armed Police Force, Tianjin, PR China; Pingjin Hospital, Logistics University of the Chinese People's Armed Police Forces, Tianjin, PR China
| | - Yu-ming Li
- Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, Logistics University of the Chinese People's Armed Police Force, Tianjin, PR China
| | - Hong Chen
- Department of Pharmacognosy and Pharmaceutics, Logistics University of the Chinese People's Armed Police Force, Tianjin, PR China; Tianjin Key Laboratory for Prevention and Control of Occupational and Environmental Hazard, Logistics University of the Chinese People's Armed Police Force, Tianjin, PR China.
| |
Collapse
|